Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Probable E3 ubiquitin-protein ligase which mediates ubiquitination and subsequent proteasomal degradation of target proteins.
Showing 10 out of 14 products:
nuclear localization of Ran was strongly increased in MYCBP2-deficient DRGs
Arf-bp1 and Pam (show PAM Antibodies) are novel regulators of circadian gene expression that target Rev-erb alpha (show NR1D1 Antibodies) for degradation
Mycbp2 and Robo2 (show ROBO2 Antibodies) were found to cooperate within a genetic network that has profound effects on axon guidance
Phr1 (show PLEKHB1 Antibodies) is identified as a key regulator of a core axon degeneration program that balances axon survival and loss in various neuronal cell types.
The ubiquitin ligase (show RNF123 Antibodies) complex containing Pam (show PAM Antibodies)-Fbxo45 (show FBXO45 Antibodies) likely targets additional synaptic and axonal proteins, which may explain the overlapping neurodevelopmental defects observed in Phr1 (show PLEKHB1 Antibodies) and Fbxo45 (show FBXO45 Antibodies) deficiency.
These results show that Phr1 (show PLEKHB1 Antibodies) is an essential regulator of retinal ganglion cell projection during both dLGN and SC topographic map development.
p38 MAPK (show MAPK14 Antibodies) activation can inhibit activity-induced ion channel internalization and MYCBP2 regulates internalization of TRPV1 (show TRPV1 Antibodies) in peripheral sensory neurons as well as duration of thermal hyperalgesia through p38 MAPK (show MAPK14 Antibodies)
Structures of both the first and second PHR domains of Mus (show TRPV6 Antibodies) musculus (mouse) Phr1 (MYC binding protein 2, Mycbp2) have been determined, revealing a novel beta sandwich fold composed of 11 antiparallel beta-strands.
Phr1 (show PLEKHB1 Antibodies) is required for formation of major CNS axon tracts via a mechanism that is both cell-nonautonomous and independent of DLK (show DAPK3 Antibodies).
Thus, efficacious pathfinding requires Phr1 (show PLEKHB1 Antibodies) activity for coordinating the cytoskeletal organization that distinguishes axons from growth cones.
Data indicate an oncogenic role for an Ikaros (show IKZF1 Antibodies) protein/MYCBP2 protein/proto-oncogene (show RAB1A Antibodies) protein c (show PROC Antibodies)-MYC (show MYC Antibodies) axis in adult acute lymphoblastic leukemia (ALL), providing a mechanism of target therapies that activate Ikaros (show IKZF1 Antibodies) in ALL.
Arf-bp1 (show HUWE1 Antibodies) and Pam (show PAM Antibodies) are novel regulators of circadian gene expression that target Rev-erb alpha (show NR1D1 Antibodies) for degradation
Data show that epithelial-mesenchymal transition (EMT (show ITK Antibodies))-transcription factors can be dynamically degraded by an atypical ubiquitin E3 ligase complex Skp1 (show SKP1 Antibodies)-Pam (show PAM Antibodies)-Fbxo45 (show FBXO45 Antibodies) (SPFFbxo45).
In castration resistant prostate cancer, MYCBP2 is down-regulated at the mRNA and protein levels.
We describe a distinct excavated optic disc anomaly associated with high myopia and increased axial length. The condition appears to follow an autosomal dominant pattern and segregate with a deletion in MYCBP2.
Pam (show PAM Antibodies), through its interaction with tuberin (show TSC2 Antibodies), could regulate the ubiquitination and proteasomal degradation of the tuberin (show TSC2 Antibodies)-hamartin (show TSC1 Antibodies) complex particularly in the CNS
PAM (show PAM Antibodies) the longest lasting nontranscriptional regulator of adenylyl cyclase activity known to date and presents a novel mechanism for the temporal regulation of cAMP signaling
Identifies the region in PAM (show PAM Antibodies) that inhibits the domain of type V adenylyl cyclase.
PAM (show PAM Antibodies) protein activated by facilitating the GDP/GTP (show AK3 Antibodies)-exchange of RHEBL1 (show RHEBL1 Antibodies) protein which is an activator of mTOR (show FRAP1 Antibodies) protein.
Probable E3 ubiquitin-protein ligase which mediates ubiquitination and subsequent proteasomal degradation of target proteins. May function as a facilitator or regulator of transcriptional activation by MYC. May have a role during synaptogenesis.
Myc-binding protein 2
, pam, highwire, rpm 1
, pam/highwire/rpm-1 protein
, probable E3 ubiquitin-protein ligase MYCBP2
, protein associated with Myc
, myc-binding protein 2